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Introduction
Treatment of infections caused by multidrug-resistant (MDR) Enterobacteriaceae represents a continuous challenge. These pathogens are frequently resistant to extended-spectrum cephalosporins owing to the production of extended-spectrum lactamases (ESBLs) and/or plasmid-mediated AmpC -lactamases (pAmpCs) [1] [2] [3] .
Moreover, even the last therapeutic options, namely carbapenems and polymyxins, are under attack due to the spread of carbapenemase-and/or MCR-1/2-producing strains, respectively [4, 5] .
In this overall scenario, the use of bacteriophages (highly species-specific selfpropagating viruses that can infect and lyse bacteria) could represent a valid therapeutic alternative to treat infections caused by extended-spectrum cephalosporin-and/or carbapenem-resistant Gram-negative pathogens [6, 7] . Bacteriophage therapy is part of the standard medical practice in the former Soviet Union countries. In contrast, in Western nations the use of phage therapy is unfamiliar and this has generated a lack of clinical studies analysing the efficacy of this possible alternative therapeutic approach [6, 7] . Therefore, most of the available scientific literature in English presents data obtained only with animal models. For instance, bacteriophage treatment was effective in in vivo models with ESBL-producing Escherichia coli, including those belonging to the hyperepidemic clone of sequence type 131 (ST131) [8] [9] [10] .
Whilst data regarding the in vitro activity of bacteriophages against E. coli and Staphylococcus aureus are available, studies analysing their activity against large 5 collections of MDR Enterobacteriaceae are very limited. Fitzgerald-Hughes et al. showed that 89% of human ESBL-producing E. coli isolates were susceptible to at least one of four bacteriophage cocktails [11] . However, strains were defined as ESBL-producers only using the phenotypic European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria; moreover, pAmpC-or carbapenemases-producers were not tested and multilocus sequence typing (MLST) was not performed to define the ST [11] . In another study, Sybesma et al. assessed the susceptibility of ESBL-producing E. coli and Klebsiella pneumoniae strains, all isolated from patients suffering from urinary tract infection (UTI), to four Georgian bacteriophage cocktails and several mono-phage preparations [12] . Their results showed great variability, with lytic activity ranging from 66% to 93% for E. coli and from 0% to 100% for K. pneumoniae [12] . Consistent results were also obtained by Gundogdu et al. who recently tested ESBL-producing E. coli from patients' blood and urine samples [13] . However, for these two latter studies, ESBL production was only phenotypically defined and no information on the ST or resistance gene profiles of the bacteria was presented [12, 13] .
To our knowledge, the activity of commercially available bacteriophage cocktails against well-defined MDR E. coli strains of animal and food origin has never been described. In the same context, data regarding Proteus spp. isolates detected in different settings are completely lacking. Therefore, in this work we aimed to assess the lytic effect of three commercial bacteriophage preparations, all available to the public in Georgia, on a large collection of well-characterised human and non-human E. coli and Proteus spp. strains. 6 
Materials and methods

Bacteriophage cocktails
Three commercially available bacteriophage cocktails produced by Georgian institutions located in Tbilisi were tested. According to the manufacturers, they are all sterile-filtrate phage lysates of different bacterial species as listed below. The preparation lot numbers implemented during the present work are indicated in parentheses, along with the declared phage concentration specified by the provider. Enterococcus spp. The specified concentration was 1  10 5-6 PFU/mL. 8 colistin-resistant strains were also included, one of which carried the mcr-1 resistance gene [5] .
In addition, 21 well-characterised P. mirabilis of human (n = 18) and food (n = 3) origin [3] were tested, along with 10 P. vulgaris responsible for human bacteraemia at Bern University Hospital, University of Bern (Bern, Switzerland). Overall, 7 ESBL-producers (4 VEB, 2 TEM and one CTX-M), 6 pAmpC-producers (all CMY-2), 1 with CTX-M-9-/CMY-2-like and 1 carbapenemase (NDM)-producer were tested. Most strains (27/31, 87%) were detected in the last 5 years (2016, n = 9; 2015, n = 5; 2014, n = 6; 2013, n = 3; and 2012, n = 4) ( All of the susceptibility tests were performed at the Institute for Infectious Diseases of the University of Bern between 29 August 2016 and 6 October 2016 by two of the authors (OJB and RT). The spot test was performed two times on different days, using vials belonging to different boxes (except for PYO, for which two vials of the same box were tested) and BHI broth/agar plates prepared in different sessions. Results were interpreted by at least three operators and showed consistency for all tested strains, with no difference greater than one '+' between the two experiments (with very few exceptions, for which a third assay was performed).
Susceptibility to bacteriophage cocktails
Results and discussion
Escherichia coli strains
As shown in Table 3 , the overall susceptibility of E. coli strains to PYO, INTESTI and Septaphage was 61.4% (including 7/70 with '+++' and 6/70 with '++++'), 67.1% (including 9/70 with '+++' and 5/70 with '++++') and 8.6% (including 4/70 with '++++'), respectively.
In particular, PYO cocktail showed lytic activity against 67.7% (21/31), 50.0% (11/12) and 66.7% (8/12) of human, animal and food strains, whereas the activities for INTESTI were 64.5% (20/31), 63.6% (14/22) and 75.0% (9/12), respectively ( Table 1) .
For the overall subgroup of the ESBL-producing E. coli strains (n = 37), the following susceptible rates were recorded: PYO, 54.0%; INTESTI, 56.7%; and Septaphage, 2.7% (Table 3 ). In the study by Fitzgerald-Hughes et al., 100 phenotypically defined ESBLproducing E. coli were susceptible to PYO and INTESTI in 36% and 54% of cases, respectively [11] . Septaphage was not tested, but the authors indicated that two additional phage cocktails, not tested in the present study, were much more active (i.e. SES and ENKO, at 87% and 89%, respectively) [11] . In another analysis testing only nine ESBLproducing E. coli strains, Sybesma et al. obtained the following susceptibility rates: PYO, 78%; and INTESTI, SES and ENKO, all 89% [12] .
With regard to the pAmpC-producing E. coli strains (n = 21), 71.4% and 85.7% were susceptible to PYO and INTESTI, respectively, whereas only 14.3% were susceptible to Septaphage. Moreover, five of seven carbapenemase-producers and three of four colistin-resistant strains (including the MCR-1-producer) were susceptible to PYO and INTESTI, respectively (Tables 1 and 3 ). We highlight that no previous studies have analysed the lytic activity of commercial bacteriophage cocktails against this specific group of MDR E. coli strains. Data regarding the life-threatening carbapenem-and colistin-resistant strains were promising [4, 5, 21] but should be confirmed testing a larger collection of strains.
In this study, five of seven E. coli strains belonging to the hyperepidemic clones ST131 and ST648 [22] were susceptible both to PYO and INTESTI (Tables 1 and 3 ). We also emphasise that the activity of the phage compounds was relatively different even though the E. coli strains belonged to the same STs (e.g. see the results of the five ST131 and four ST420 strains in Table 1 ). These differences probably depend on the fact that some bacterial clones may acquire and develop different escape strategies (e.g. inhibition of CRISPR-Cas or phage adsorption systems) against bacteriophages [23] . Therefore, as recently explored for S. Typhimurium [24] , further studies with a larger collection of hyperepidemic E. coli clones coupled with whole-genome sequence analyses should be performed to clarify the underlying molecular mechanisms that make each unique bacteria resistant to phage attack.
Proteus spp. strains
As anticipated, published data regarding the activity of commercial bacteriophage cocktails against Proteus spp. strains are lacking. In the present study, the overall susceptibility of Proteus spp. to PYO, INTESTI and Septaphage was 29.0% (including 3/31 with '+++' or '++++'), 38.7% (including 4/31 with '+++' or '++++') and 19.3% (including 5/31 with '+++' or '++++'), respectively ( Table 2 and 3 ). In particular, the following susceptibility rates were recorded for P. mirabilis and P. vulgaris, respectively: PYO, 33 .3% and 20.0%; INTESTI, 47.6% and 20.0%, and Septaphage, 28.6% and 0%. With regard to the MDR P. mirabilis strains (n = 15), 40.0% were susceptible both to PYO and INTESTI, whereas only 26.7% were susceptible to Septaphage (Table 3 ). Owing to the relatively small number of tested strains, larger collections of MDR Proteus spp. should be tested to confirm these results.
Overall strains
Surprisingly, Septaphage displayed an almost complete lack of activity both against E. coli and Proteus spp. strains. Moreover, a noteworthy variability between the two preparations expected to target the same bacterial species (i.e. INTESTI and Septaphage) could be noted (Table 3 ). This may be linked to the different content in terms of strains-specific bacteriophages with lytic activity. However, to our knowledge, only the INTESTI preparation has been well characterised using metagenomic analyses [25] .
Alternatively, the reason for such remarkable divergences among the phage compounds could rely on different production methods [26] , leading to insufficient viral titre of the final biopreparation. In this context, we note that a concentration of 10 5-6 PFU/mL is indicated both for INTESTI and PYO, whereas the concentration is 10 5 PFU/mL for Septaphage.
The overall narrow spectrum of activity of the cocktails observed against the MDR E. coli and Proteus spp. analysed in this study could be related to the absence of specific bacteriophages targeting these contemporary strains that are usually responsible for 13 human infections both in hospital and community settings [17, 22, [27] [28] [29] . Besides, it is remarkable that most of the fully antibiotic-sensitive P. mirabilis and P. vulgaris strains (10/16; 62.5%) were shown to be completely resistant to the bacteriophage cocktails with declared activity against such species.
Therefore, the spectrum of activity of the above cocktails should be expanded integrating new lytic phages. We note for instance that Dufour et al. have recently selected a bacteriophage (LM33_P1) with lytic activity against ca. 65% of ST131 E. coli isolates tested and also able to significantly reduce the organ bacterial load in pneumonia, septicaemia and UTI in in vivo models [9] . Pouillot et al. isolated another bacteriophage (EC200 PP ) specific for E. coli ST131: although no data regarding its spectrum of activity against a collection of ST131 strains was provided, this phage demonstrated potent activity in sepsis and meningitis in vivo models [10] .
A limited number of bacteriophages infecting Proteus spp. have so far been selected and studied [30, 31] . Nevertheless, we underline that Melo et al. have recently isolated and characterised a novel bacteriophage (Pm5461) that was able to target all 26 Proteus spp.
tested in the study. Unfortunately, the antimicrobial susceptibility phenotype of the strains and their year of collection were not defined [32] .
Finally, we should note that the spot test can lead to an overestimation of positive results as a consequence of the 'lysis-from-without' phenomenon [33] . We are therefore aware that the results of the current study might partially overestimate the susceptibility results for PYO and INTESTI compounds.
Conclusions
Escherichia coli and Proteus spp. are frequently responsible for UTIs and bacteraemia [27, 34] . Furthermore, difficult-to-treat infections due to MDR E. coli and Proteus spp. are increasing worldwide, leading to higher morbidity and mortality rates [1, 28, 29, 35] . We also note that such MDR pathogens can cause intestinal colonisation of humans [5, 16] and animals [2, 14, 18, 21] , along with contamination of the food chain [3, 36, 37] . Since exchange of MDR strains among these settings has been demonstrated [2, 18] , this overall phenomenon, also known as the 'One-Health concept', contributes enormously to the expansion and spread of MDR Enterobacteriaceae [38] .
In this scenario, we therefore explored the use of bacteriophages as a possible alternative to antibiotics. In particular, we assessed for the first time the in vitro susceptibility of a large collection of well-characterised E. coli and Proteus spp. to three commercial bacteriophage cocktails. This information is essential to understand whether these phage compounds can be hypothetically implemented in large scale to treat infections (e.g. UTIs) [6, 7] , to decolonise intestinal carriers and/or to decontaminate food stuffs [39] from current MDR E. coli and Proteus spp.
As a result of the analysis, we observed neither strong lysis ('+++' to '++++') for the majority of the tested strains, nor a wide spectrum of activity against the total number of bacteria, especially regarding Proteus spp. The most active compound (INTESTI) showed ca. 70% and 40% activity against E. coli and Proteus spp., respectively (although only 15-20% with activity ≥ '+++').
The great diversity of currently circulating MDR E. coli and Proteus spp. is partially exemplified by the bacterial collection studied here. The tested cocktails contained only a few bacterial viruses targeting such contemporary pathogens. Therefore, new bacteriophages active against emerging MDR strains need to be isolated and integrated in such biopreparations. Only in this way will phage libraries start to reflect the worldwide and actual situation of MDR and pandemic isolates [22] . Moreover, the newly isolated bacteriophages should also be well characterised [9, 10, 25, 32] and should be produced according to Good Manufacturing Practice (GMP) standards in order to become, at a later stage, approved for clinical therapy [7, 26] .
To become a real alternative to standard antimicrobials, phage cocktails first need to be brought up to date in terms of clinically relevant strain-specific viral content [40] . Only then will the progress towards therapeutic use of bacteriophages for the management of difficult-to-treat infections caused by MDR organisms meet a ground to grow and flourish also in the Western world. commercial phage cocktails during a trip to Georgia. The authors also thank Dr Natia Karumidze for her precious suggestions during her stay ( Strains showing no activity (i.e. no clearing: 'R') were defined as resistant. c -Indicates no bla genes conferring resistance to extended-spectrum cephalosporins. 
